Intervention Review

You have free access to this content

Pathogen-reduced platelets for the prevention of bleeding

  1. Caroline Butler1,
  2. Carolyn Doree2,
  3. Lise J Estcourt3,
  4. Marialena Trivella4,
  5. Sally Hopewell5,
  6. Susan J Brunskill2,
  7. Simon Stanworth3,
  8. Michael F Murphy6,*

Editorial Group: Cochrane Haematological Malignancies Group

Published Online: 28 MAR 2013

Assessed as up-to-date: 25 FEB 2013

DOI: 10.1002/14651858.CD009072.pub2


How to Cite

Butler C, Doree C, Estcourt LJ, Trivella M, Hopewell S, Brunskill SJ, Stanworth S, Murphy MF. Pathogen-reduced platelets for the prevention of bleeding. Cochrane Database of Systematic Reviews 2013, Issue 3. Art. No.: CD009072. DOI: 10.1002/14651858.CD009072.pub2.

Author Information

  1. 1

    Oxford Radcliffe Hospital NHS Trust, Haematology Department, Maidenhead, UK

  2. 2

    NHS Blood and Transplant, Systematic Review Initiative, Oxford, UK

  3. 3

    NHS Blood and Transplant, Haematology/Transfusion Medicine, Oxford, UK

  4. 4

    The Cochrane Collaboration, Cochrane Operations Unit, Oxford, UK

  5. 5

    University of Oxford, Centre for Statistics in Medicine, Oxford, Oxfordshire, UK

  6. 6

    John Radcliffe Hospital, NHS Blood and Transplant, Oxford, UK

*Michael F Murphy, NHS Blood and Transplant, John Radcliffe Hospital, Headley Way, Headington, Oxford, OX3 9BQ, UK. mike.murphy@nhsbt.nhs.uk.

Publication History

  1. Publication Status: New
  2. Published Online: 28 MAR 2013

SEARCH

[Figure 1]
Figure 1. PRISMA Study Flow Diagram
[Figure 2]
Figure 2. 'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.
[Figure 3]
Figure 3. Forest plot of comparison: 1 Pathogen-reduced platelets versus standard platelets, outcome: 1.1 Number of participants with 'any bleeding' event(s) (WHO grade 1-4 or equivalent) - follow-up < 48 hrs.
[Figure 4]
Figure 4. Forest plot of comparison: 1 Pathogen-reduced platelets versus standard platelets, outcome: 1.2 Number of participants with 'any bleeding' event(s) (WHO grade 1-4 or equivalent) - follow-up > 7 days.
[Figure 5]
Figure 5. Forest plot of comparison: 1 Pathogen-reduced platelets versus standard platelets, outcome: 1.3 Number of participants with a 'clinically significant' bleeding event(s) (WHO grade ≥ 2 of equivalent) - follow-up > 7 days.
[Figure 6]
Figure 6. Forest plot of comparison: 1 Pathogen-reduced platelets versus standard platelets, outcome: 1.4 Number of participants with a 'severe' bleeding event(s) (WHO grade ≥ 3 of equivalent) - follow-up > 7 days.
[Figure 7]
Figure 7. Forest plot of comparison: 1 Pathogen-reduced platelets versus standard platelets, outcome: 1.5 All-cause mortality post-transfusion (follow-up 0 to 12 weeks).
[Analysis 1.1]
Analysis 1.1. Comparison 1 Pathogen-reduced platelets versus standard platelets, Outcome 1 Number of participants with 'any bleeding' event(s) (WHO grade 1-4 or equivalent) - follow-up < 48 hrs.
[Analysis 1.2]
Analysis 1.2. Comparison 1 Pathogen-reduced platelets versus standard platelets, Outcome 2 Number of participants with 'any bleeding' event(s) (WHO grade 1-4 or equivalent) - follow-up > 7 days.
[Analysis 1.3]
Analysis 1.3. Comparison 1 Pathogen-reduced platelets versus standard platelets, Outcome 3 Number of participants with a 'clinically significant' bleeding event(s) (WHO grade ≥ 2 of equivalent) - follow-up > 7 days.
[Analysis 1.4]
Analysis 1.4. Comparison 1 Pathogen-reduced platelets versus standard platelets, Outcome 4 Number of participants with a 'severe' bleeding event(s) (WHO grade ≥ 3 of equivalent) - follow-up > 7 days.
[Analysis 1.5]
Analysis 1.5. Comparison 1 Pathogen-reduced platelets versus standard platelets, Outcome 5 All-cause mortality post-transfusion (follow-up 0 to 12 weeks).
[Analysis 1.6]
Analysis 1.6. Comparison 1 Pathogen-reduced platelets versus standard platelets, Outcome 6 Number of participants with an acute transfusion reaction.
[Analysis 1.7]
Analysis 1.7. Comparison 1 Pathogen-reduced platelets versus standard platelets, Outcome 7 Number of participants experiencing platelet refractoriness.
[Analysis 1.8]
Analysis 1.8. Comparison 1 Pathogen-reduced platelets versus standard platelets, Outcome 8 Number of participants experiencing platelet refractoriness and platelet alloimmunisation.
[Analysis 1.9]
Analysis 1.9. Comparison 1 Pathogen-reduced platelets versus standard platelets, Outcome 9 Number of participants with an adverse event.
[Analysis 1.10]
Analysis 1.10. Comparison 1 Pathogen-reduced platelets versus standard platelets, Outcome 10 Number of participants with a serious adverse event.
[Analysis 1.11]
Analysis 1.11. Comparison 1 Pathogen-reduced platelets versus standard platelets, Outcome 11 Lab response - 1-hour count increment [x 109/L].
[Analysis 1.12]
Analysis 1.12. Comparison 1 Pathogen-reduced platelets versus standard platelets, Outcome 12 Lab response - 1-hour corrected count increment (CCI) [x 103/L].
[Analysis 1.13]
Analysis 1.13. Comparison 1 Pathogen-reduced platelets versus standard platelets, Outcome 13 Lab response - 24-hour count increment [x 109/L].
[Analysis 1.14]
Analysis 1.14. Comparison 1 Pathogen-reduced platelets versus standard platelets, Outcome 14 Lab response - 24-hour corrected count increment (CCI) [x 103/L].
[Analysis 1.15]
Analysis 1.15. Comparison 1 Pathogen-reduced platelets versus standard platelets, Outcome 15 Number of platelet transfusions per patient per day of platelet support.
[Analysis 1.16]
Analysis 1.16. Comparison 1 Pathogen-reduced platelets versus standard platelets, Outcome 16 Platelet transfusion interval (days to next platelet transfusion).
[Analysis 1.17]
Analysis 1.17. Comparison 1 Pathogen-reduced platelets versus standard platelets, Outcome 17 Number of red cell transfusions per patient per day of platelet support.